Drugs / B-type Natriuretic Peptide (BNP)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00252187 Comparator | Jan 2000 → Jul 2008 | cardiomyopathy, congestive heart failure | Horng Chen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B-type Natriuretic Peptide (BNP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00252187 ↗ |
| Known as | Natrecor | “Natrecor (nesiritide) a sterile, purified preparation of human BNP is approved by the FDA for intravenous administration in the treatment of patients with acute decompensated...” NCT00252187 ↗ |
| Action | Restore | “chronic cardiac hormone replacement with BNP” NCT00252187 ↗ |
| Modality | Protein / enzyme biologic | “Subcutaneous BNP represents a novel, safe, and efficacious protein therapeutic strategy in human HF.” PMID 23122795 ↗ Nov 2012 |
| Route | Subcutaneous | “BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.” NCT00252187 ↗ |